Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$6.36
+6.6%		$8.24
$4.68
▼
$253.26
$3.27M-0.07645,564 shs587,225 shs
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shs80,048 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$0.21
$0.21
$0.21
▼
$3.09
$2.55M0.91482,532 shsN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.80
-2.2%		$2.90
$1.43
▼
$58.75
$2.67M1.8343,991 shs35,871 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%-4.23%-13.94%-53.66%-97.61%
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%0.00%0.00%0.00%-91.02%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.00%+3.95%+7.60%-64.48%-96.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$6.36
+6.6%		$8.24
$4.68
▼
$253.26
$3.27M-0.07645,564 shs587,225 shs
Athersys, Inc. stock logo
ATHX
Athersys
$0.00
$0.01
▼
$1.99
$833K-0.91.77 million shs80,048 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$0.21
$0.21
$0.21
▼
$3.09
$2.55M0.91482,532 shsN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$1.80
-2.2%		$2.90
$1.43
▼
$58.75
$2.67M1.8343,991 shs35,871 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.00%-4.23%-13.94%-53.66%-97.61%
Athersys, Inc. stock logo
ATHX
Athersys
0.00%0.00%0.00%0.00%0.00%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
0.00%0.00%0.00%0.00%-91.02%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.00%+3.95%+7.60%-64.48%-96.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
1.67
ReduceN/AN/A
Athersys, Inc. stock logo
ATHX
Athersys
0.00
N/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
2.00
Hold$4.001,827.71% Upside
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ATHX, ARTL, NXTS, and CASI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2026
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A($1.89) per shareN/A
Athersys, Inc. stock logo
ATHX
Athersys
$146K0.00N/AN/A($1.33) per share0.00
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$26.85M0.10N/AN/A$0.12 per share1.73
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
$210K12.32N/AN/A$39.70 per share0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$12.88M-$16.80N/AN/AN/AN/A-518.27%-194.29%11/17/2026 (Estimated)
Athersys, Inc. stock logo
ATHX
Athersys
-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$3.01N/AN/AN/A-183.93%N/A-131.54%N/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
-$4M-$96.07N/AN/AN/AN/A-304.79%-178.91%N/A

Latest ATHX, ARTL, NXTS, and CASI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$6.48-$8.01-$1.53-$0.89N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A
Athersys, Inc. stock logo
ATHX
Athersys
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
3.00
3.00
Athersys, Inc. stock logo
ATHX
Athersys
N/A
0.06
0.06
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.30
0.24
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
0.12
3.72
3.72

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%
Athersys, Inc. stock logo
ATHX
Athersys
19.35%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
61.24%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.20%
Athersys, Inc. stock logo
ATHX
Athersys
0.03%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
6.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
54.93 million4.77 millionNot Optionable
Athersys, Inc. stock logo
ATHX
Athersys
2461.72 million61.70 millionNo Data
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Nexentis Technologies Inc. stock logo
NXTS
Nexentis Technologies
21.45 million1.36 millionN/A

Recent News About These Companies

Nexentis Technologies Inc.: Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
July 28, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69143766-nexentis-technologies-inc-nexentis-technologies-subsidiary-mitocarex-bio-selects-transport-protein-candidate-for-drug-discovery-campaign-399.htm
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334228/0/en/nexentis-technologies-subsidiary-mitocarex-bio-selects-transport-protein-candidate-for-drug-discovery-campaign.html
Nexentis Technologies Earnings Estimates, EPS & Revenue | NASDAQ:NXTS
July 18, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NXTS/earnings
Nexentis Technologies Insider Trading Activity | NASDAQ:NXTS | Benzinga
July 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/NXTS/insider-trades
Nexentis Technologies Inc NXTS
July 7, 2026  |  morningstar.comM
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
July 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/07/3323166/0/en/nexentis-subsidiary-mitocarex-bio-advances-slc-transporter-drug-discovery-with-broad-analysis-and-international-ai-initiative.html
Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)
June 29, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/nexentis-shares-rise-after-solar-project-monetisation-agreement-nxts/ar-AA26OnVs
Nexentis Technologies Announces Addendum on Melz Solar Project Loan and Profit Rights, Reflecting $14.5 Million Project Valuation
June 29, 2026  |  quiverquant.comQ
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
June 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/29/3318926/0/en/nexentis-announces-monetization-of-part-of-its-melz-solar-investment-at-14-5-million-project-valuation-significant-premium-to-initial-investment.html
Nexentis Technologies Announces Registered Direct Offering and Warrants
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexentis-technologies-announces-registered-direct-offering-and-warrants?utm_source=marketbeat.com&utm_medium=referral
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
June 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/22/3315270/0/en/nexentis-technologies-announces-international-ai-drug-discovery-initiative-between-mitocarex-bio-and-boltz-to-accelerate-novel-slc-small-molecule-discovery.html
Nexentis shares swing after subsidiary reaches drug discovery research milestone
June 17, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/nexentis-shares-swing-after-subsidiary-reaches-drug-discovery-research-milestone/ar-AA25SEdI
Nexentis Technologies Inc. Subsidiary MitoCareX Bio Ltd. Completes Structural Analysis of SLC Transport Proteins to Enhance Drug Discovery Efforts
June 17, 2026  |  quiverquant.comQ
Nexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313343/0/en/nexentis-subsidiary-mitocarex-bio-successfully-completed-broad-analysis-of-slc-transport-proteins-to-support-discovery-of-hard-to-treat-cancers-and-metabolic-diseases.html
Nexentis Technologies Announces New Equity Financing Agreements
June 12, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexentis-technologies-announces-new-equity-financing-agreements?utm_source=marketbeat.com&utm_medium=referral
NXTS Nexentis Technologies Inc.
May 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/NXTS/sec-filings
Nexentis Expands Credit Facility Under Amended Financing Agreement
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/nexentis-expands-credit-facility-under-amended-financing-agreement?utm_source=marketbeat.com&utm_medium=referral
Nexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296731/0/en/nexentis-announces-mitocarex-bio-achieves-key-r-d-milestone-generating-a-substantially-improved-hit-molecule-on-the-path-to-pre-clinical-development.html
Nexentis Technologies Inc.: Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
May 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68484176-nexentis-technologies-inc-nexentis-technologies-announces-optimization-of-hit-molecule-at-mitocarex-bio-representing-key-drug-discovery-milestone-399.htm
Nexentis Technologies Inc. Announces Drug Discovery Milestone Achieved by MitoCareX Utilizing MITOLINE® Platform
May 13, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
SoundHound AI logo displayed within a glowing orange ring against a dark background with light wave effects.
SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat
By Thomas Hughes | August 10, 2026
Birkenstock logo displayed beside a two-strap sandal, cork material, and leather, with a neutral tan backdrop.
Birkenstock Beats the Skeptics—But Not on EPS
By Chris Markoch | August 17, 2026
Artelo Biosciences stock logo

Artelo Biosciences NASDAQ:ARTL

$6.36 +0.40 (+6.63%)
As of 04:00 PM Eastern

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

Athersys stock logo

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)
As of 08/28/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Nexentis Technologies stock logo

Nexentis Technologies NASDAQ:NXTS

$1.80 -0.04 (-2.17%)
As of 04:00 PM Eastern

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company's products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas